Helen Frankenthaler Foundation

Vasoactive Intestinal Peptide VIP

sincalide

high purity testosterone enanthate laboratory scene

sincalide

Description

An octapeptide hormone present in the intestine and brain. When secreted from the gastric mucosa, it stimulates the release of bile from the gallbladder and digestive enzymes from the pancreas.

PropertyValue
Molecular weight1143.27
FormulaC49H62N10O16S3
CLOGP-6.94
LIPINSKI3
HAC26
HDO13
TPSA426.80
ALOGS-5.41
ROTB33
StatusOFP

Synonyms: sincalide, cholecystokinin-8, SQ-19844, SQ 19844

Drug Dosage

None

ADMET Properties

None

Approvals

DateAgencyCompanyOrphan
July 21, 1976FDABRACCO-

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple use of single-use product164.01105.3921123147163487407

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple use of single-use product246.0492.162812289679743342
Therapeutic product effect decreased145.3892.163711316382679580412

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action

SourceCodeDescription
ATCV04CC03VARIOUS DIAGNOSTIC AGENTS OTHER DIAGNOSTIC AGENTS Tests for bile duct patency
FDA CSM0004235Cholecystokinin
FDA EPCN0000175798Cholecystokinin Analog

Drug Use

DiseaseRelationSNOMED_IDDOID
Diagnostic aidindication2949005
Diagnostic Test for Pancreas Functionindication
Gastrointestinal obstructioncontraindication126765001
Pregnancy, functioncontraindication289908002
Gallstone Complicationscontraindication
Veterinary Drug Use

None

Veterinary products

None

Acid Dissociation Constants

Dissociation levelDissociation constantType (acidic/basic)
pKa12.68acidic
pKa23.79acidic
pKa312.75acidic
pKa412.79acidic
pKa513.18acidic
pKa613.27acidic
pKa713.67acidic
pKa813.79acidic
pKa98.42Basic

Orange Book Patent Data

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
0.005MG/VIALSINCALIDEMAIA PHARMS INCN210850Nov. 22, 2022RXPOWDERINTRAVENOUS11110063April 20, 2038DIAGNOSIS OF GALL BLADDER DISORDERS OR OTHER DIAGNOSTIC IMAGING BY STIMULATING GALLBLADDER CONTRACTION, AS MAY BE ASSESSED BY VARIOUS METHODS OF DIAGNOSTIC IMAGING, OR TO OBTAIN BY DUODENAL ASPIRATION A SAMPLE OF CONCENTRATED BILE FOR ANALYSIS
0.005MG/VIALSINCALIDEMAIA PHARMS INCN210850Nov. 22, 2022RXPOWDERINTRAVENOUS11110063April 20, 2038DIAGNOSIS OF PANCREATIC DISORDERS BY STIMULATING PANCREATIC SECRETION IN COMBINATION WITH SECRETIN PRIOR TO OBTAINING A DUODENAL ASPIRATE FOR ANALYSIS
0.005MG/VIALSINCALIDEMAIA PHARMS INCN210850Nov. 22, 2022RXPOWDERINTRAVENOUS11110063April 20, 2038DIAGNOSTIC IMAGING BY ACCELERATING THE TRAN IT OFA BARIUM MEAL THROUGH THE SMALL BOWEL, THEREBY DECREASING THE TIME AND EXTENT OF RADIATION ASSOCIATED WITH FLUOROSCOPY AND X-RAY EXAMINATION OF THE INTESTINAL TRACT
0.005MG/VIALSINCALIDEMAIA PHARMS INCN210850Nov. 22, 2022RXPOWDERINTRAVENOUS11318100April 20, 2038ACCELERATE THE TRANSIT OF A BARIUM MEAL THROUGH THE SMALL BOWEL, THEREBY DECREASING THE TIME AND EXTENT OF RADIATION ASSOCIATED WITH FLUOROSCOPY AND X-RAY EXAMINATION OF THE INTESTINAL TRACT
0.005MG/VIALSINCALIDEMAIA PHARMS INCN210850Nov. 22, 2022RXPOWDERINTRAVENOUS11318100April 20, 2038STIMULATE GALLBLADDER CONTRACTION, AS MAY BE ASSESSED BY VARIOUS METHODS OF DIAGNOSTIC IMAGING, OR TO OBTAIN BY DUODENAL ASPIRATION A SAMPLE OF CONCENTRATED BILE FOR ANALYSIS
0.005MG/VIALSINCALIDEMAIA PHARMS INCN210850Nov. 22, 2022RXPOWDERINTRAVENOUS11318100April 20, 2038STIMULATE GALLBLADDER CONTRACTION. AS MAY BE ASSESSED BY VARIOUS METHODS OF DIAGNOSTIC IMAGING, OR TO OBTAIN BY DUODENAL ASPIRATION A SAMPLE OF CONCENTRATED BILE FOR ANALYSIS
0.005MG/VIALSINCALIDEMAIA PHARMS INCN210850Nov. 22, 2022RXPOWDERINTRAVENOUS11318100April 20, 2038STIMULATE PANCREATIC SECRETION IN COMBINATION WITH SECRETIN PRIOR TO OBTAINING A DUODENAL ASPIRATE FOR ANALYSIS

Orange Book Exclusivity Data

None

Bioactivity Summary

TargetClassUniProtActionTypeActivity value (-log[M])Mechanism actionBioact sourceMoA source
Cholecystokinin receptor type AGPCRCCKAR_HUMANKi9.55-CHEMBL
Gastrin/cholecystokinin type B receptorGPCRGASR_HUMANKi9.55-CHEMBL
Cholecystokinin receptor type AGPCRCCKAR_RATKi10.05-CHEMBL
Gastrin/cholecystokinin type B receptorGPCRGASR_RATKi9.39-CHEMBL
Gastrin/cholecystokinin type B receptorGPCRGASR_MOUSEIC509.52-CHEMBL
Cholecystokinin receptor type AGPCRCCKAR_CAVPOKi9.55-CHEMBL
Cholecystokinin receptorGPCRCCKAR_MOUSE GASR_MOUSEKi9.52-CHEMBL

External Reference

IDSource
001215NDDF
126222003SNOMEDCT_US
35765001SNOMEDCT_US
3617INN_ID
367299MMSL
4017721VUID
4017721VANDF
5466MMSL
9800RXNORM
9833444PUBCHEM_CID

Pharmaceutical Products

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
KINEVACHUMAN PRESCRIPTION DRUG LABEL10270-0556INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION5 ugINTRAVENOUSNDA24 sections
KINEVACHUMAN PRESCRIPTION DRUG LABEL10270-0556INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION5 ugINTRAVENOUSNDA24 sections
KINEVACHUMAN PRESCRIPTION DRUG LABEL10270-0556INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION5 ugINTRAVENOUSNDA24 sections
SIncalideHUMAN PRESCRIPTION DRUG LABEL151808-203INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION3 ugINTRAVENOUSUnapproved drug other8 sections
SINCALIDE